Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of MG-ZG122 in adults with moderate-to-severe asthma
CTR20251689Phase 2Active
- Sponsor
- Medigene AG
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MG-ZG122 in asthma (4 arms), sponsored by Medigene AG. Primary endpoint: Annualized rate of severe asthma exacerbations over 48 weeks. Started Aug 2025; status: active.
02
Drugs
MG-ZG122
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20251689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251689.